HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| Line 1,467: | Line 1,467: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
| | |Karin Miller, MD | ||
| | |10/9/2025 | ||
| | | | ||
| | | | ||
| Line 1,483: | Line 1,483: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | ||
|Disease | |Disease | ||
|Mark Evans, MD; Kilannin Krysiak, PhD | |Mark G. Evans, MD; Kilannin Krysiak, PhD | ||
|10/1/2025 | |10/1/2025 | ||
| | | | ||
| Line 1,499: | Line 1,499: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
| | |Gokce A. Toruner, MD, PhD | ||
| | |10/9/2025 | ||
| | | | ||
| | | | ||
| Line 1,515: | Line 1,515: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | ||
|Disease | |Disease | ||
| | |Gokce A. Toruner, MD, PhD | ||
| | |10/8/2025 | ||
| | | | ||
| | | | ||
| Line 1,548: | Line 1,548: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | ||
|Disease | |Disease | ||
|Miguel Gonzalez Mancera | |Miguel Gonzalez Mancera, MD | ||
| | | | ||
| | | | ||
| Line 1,564: | Line 1,564: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | ||
|Disease | |Disease | ||
|Miguel Gonzalez Mancera | |Miguel Gonzalez Mancera, MD | ||
| | | | ||
| | | | ||
| Line 1,613: | Line 1,613: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]] | ||
|Disease | |Disease | ||
| | |Karin Miller, MD | ||
| | |10/9/2025 | ||
| | | | ||
| | | | ||